the trail [100000:2.5 > 1.5 to 2.5 3 12 Prevention of CMV Disease in Solid Organ Transplant Patients: Table 5 shows selected adverse reactions regardless of severity with an incidence of greater than or equal to 5% from a clinical trial (up to 28 days after study treatment) where heart, kidney, kidney-pancreas and liver transplant patients received Valganciclovir tablets (N=244) or oral ganciclovir (N=126) until Day 100 post-transplant. The majority of the adverse reactions were of mild or moderate intensity. Table 5 Percentage of Selected Grades 1 to 4 Adverse Reactions Reported in greater than or equal to 5% of Adult Patients From a Study of Selected Solid Organ Transplant Patients Adverse Reactions Valganciclovir Tablets (N=244) % Oral Ganciclovir (N=126) % Gastrointestinal disorders Diarrhea 30 29 Nausea 23 23 Vomiting 16 14 Nervous system disorders Tremors 28 25 Headache 22 27 Insomnia 20 16 General disorders and administration site conditions Pyrexia 13 14 Table 6 shows selected adverse reactions regardless of severity with an incidence of greater than or equal to 5% from another clinical trial where kidney transplant patients received either Valganciclovir once daily starting within 10 days post-transplant until Day 100 post-transplant followed by 100 days of placebo or Valganciclovir once daily until Day 200 post-transplant. The overall safety profile of Valganciclovir did not change with the extension of prophylaxis until Day 200 post-transplant in high risk kidney transplant patients. Table 6 Percentage of Selected Grades 1-4 Adverse Reactions Reported in greater than or equal to 5% of Patients from a Study of Kidney Transplant Patients Adverse Reactions Valganciclovir Tablets Day 100 Post-transplant (N=164) % Valganciclovir Tablets Day 200 Post-transplant (N=156) % Gastrointestinal disorders Diarrhea 26 31 Nausea 11 11 Vomiting 3 6 Nervous system disorders Tremors 12 17 Headache 10 6 Insomnia 7 6 General disorders and administration site conditions Pyrexia 12 9 Tables 7 and 8 show selected laboratory abnormalities reported with Valganciclovir tablets in two trials in solid organ transplant patients. Table 7 Selected Laboratory Abnormalities Reported in a Study of Adult Solid Organ Transplant Patients* Laboratory Abnormalities Valganciclovir Tablets (N=244) % Ganciclovir Capsules (N=126) % Neutropenia: ANC/μL] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturers Dr. Reddy's Laboratories, Inc. Teva Pharmaceuticals USA, Inc. Aurobindo Pharma Limited Camber Pharmaceuticals, Inc. More... Drug Class Purine nucleosides Related Drugs purine nucleosides acyclovir , valacyclovir , Valtrex , Zovirax , famciclovir , Famvir CMV Prophylaxis valacyclovir , Valcyte , ganciclovir , Prevymis , cytomegalovirus immune globulin , CytoGam , Cytovene , More... CMV Retinitis Valcyte , ganciclovir , foscarnet , cidofovir , Foscavir , Cytovene , Vistide , More... Valganciclovir Rating 1 User Review 8.0 /10 1 User Review 8.0 Rate it! Valganciclovir Images Valganciclovir systemic 450 mg (E114 ) View all images it's also
which ends up in Valganciclovir by the way
EmoticonEmoticon